These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. 123I-IBZM binding compared with long-term clinical follow up in patients with de novo parkinsonism. Schwarz J; Tatsch K; Gasser T; Arnold G; Pogarell O; Künig G; Oertel WH Mov Disord; 1998 Jan; 13(1):16-9. PubMed ID: 9452320 [TBL] [Abstract][Full Text] [Related]
23. Levodopa effective parkinsonism associated with aqueductal stenosis: a case report and review of the literature. Asamoto S; Sugiyama H; Doi H; Yokochi M; Hirabayashi K; Tanaka S; Sugiura K; Nakama H; Matsumoto K No Shinkei Geka; 1998 Dec; 26(12):1089-92. PubMed ID: 9883448 [TBL] [Abstract][Full Text] [Related]
24. [Difficulties and errors in ambulatory therapy of Parkinson disease]. Braunschweiger-Brixel EM; Finck GA; Schiffter R Z Gerontol; 1991; 24(1):39-44. PubMed ID: 2038889 [TBL] [Abstract][Full Text] [Related]
26. A family with hereditary juvenile dystonia-parkinsonism. Ishikawa A; Miyatake T Mov Disord; 1995 Jul; 10(4):482-8. PubMed ID: 7565830 [TBL] [Abstract][Full Text] [Related]
27. Clinical observations in early and late onset Parkinson's disease. Bostantjopoulou S; Logothetis J; Katsarou Z; Mentenopoulos G Funct Neurol; 1991; 6(2):145-9. PubMed ID: 1916456 [TBL] [Abstract][Full Text] [Related]
28. [Use of the preparation L-dopa in parkinsonism]. Proniv DI; Sirotina OS; Bukhovtsev PP; Mis'kiv IaI Vrach Delo; 1976 Jan; (1):113-6. PubMed ID: 1246837 [No Abstract] [Full Text] [Related]
29. Report on 45-month treatment of parkinsonism with L-dopa, alone and in association with a decarboxilase inhibitor (Ro 4-4602). Chouza C; Romero S; Gomensoro JB Acta Neurol Latinoam; 1974; 20(1-4):116-38. PubMed ID: 4619960 [No Abstract] [Full Text] [Related]
30. [A family of parkinsonism in which the clinical feature of constituents varied with the age of onset]. Sasaki R; Kuzuhara S; Taniguchi A; Narita Y; Naito Y Rinsho Shinkeigaku; 1994 Jul; 34(7):736-8. PubMed ID: 7955737 [TBL] [Abstract][Full Text] [Related]
31. [Juvenile parkinsonism in monozygotic twins]. Umehara F; Nomoto M; Usuki F; Matsumoto W; Osame M Rinsho Shinkeigaku; 1991 Mar; 31(3):306-9. PubMed ID: 1893671 [TBL] [Abstract][Full Text] [Related]
32. [Apomorphine test: evaluation of dopaminergic response in patients with Parkinson disease]. Miranda M; Saéz D Rev Med Chil; 1995 Mar; 123(3):326-9. PubMed ID: 8525172 [TBL] [Abstract][Full Text] [Related]
34. [Clinical significance of pyridoxine administration in L-dopa therapy of Parkinsonism (author's transl)]. Namba S; Ishimitsu H; Nakasone S No To Shinkei; 1980 Oct; 32(10):991-1000. PubMed ID: 6159908 [No Abstract] [Full Text] [Related]
35. The protective role of levodopa in the human substantia nigra. Rajput AH Adv Neurol; 2001; 86():327-36. PubMed ID: 11553992 [TBL] [Abstract][Full Text] [Related]
37. Clinical features and medical treatment of Parkinson's disease in patient groups selected in accordance with age at onset. Pantelatos A; Fornadi F Adv Neurol; 1993; 60():690-7. PubMed ID: 8420212 [TBL] [Abstract][Full Text] [Related]
38. Treatment of parkinsonism by dopaflex (L-DOPA). Grbesa B; Velicković A Ther Hung; 1977; 25(3):106-8. PubMed ID: 929475 [No Abstract] [Full Text] [Related]
39. [Long-term results of L-dopa treatment of parkinsonism]. Barbeau A Union Med Can; 1975 Jan; 104(1):32-8. PubMed ID: 1111195 [No Abstract] [Full Text] [Related]